Clinical Trials Directory

Trials / Completed

CompletedNCT00463437

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,437 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
11 Months – 18 Months
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the safety in terms of fever (rectal temperature) higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK1024850A at 11 to 18 months of age in children previously primed with the same vaccines including a pneumococcal conjugate vaccine co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined and meningococcal serogroup C (MenC) or combined meningococcal serogroup C and Haemophilus influenzae type b (Hib-MenC) vaccine. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00334334).

Detailed description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPneumococcal conjugate vaccine GSK1024850AIntramuscular injection, 1 dose.
BIOLOGICALPrevenarIntramuscular injection, 1 dose.
BIOLOGICALInfanrix hexaIntramuscular injection, 1 dose. In Germany and Poland.
BIOLOGICALInfanrix IPV HibIntramuscular injection, 1 dose. In Spain.
BIOLOGICALInfanrix pentaIntramuscular injection, 1 dose. In Germany and Poland.
BIOLOGICALInfanrix IPVIntramuscular injection, 1 dose. In Spain.
BIOLOGICALMeningitecIntramuscular injection, 1 dose.
BIOLOGICALNeisVac-CIntramuscular injection, 1 dose.
BIOLOGICALMenitorixIntramuscular injection, 1 dose.

Timeline

Start date
2007-04-25
Primary completion
2008-01-21
Completion
2008-06-14
First posted
2007-04-20
Last updated
2020-01-02
Results posted
2009-08-03

Locations

63 sites across 3 countries: Germany, Poland, Spain

Source: ClinicalTrials.gov record NCT00463437. Inclusion in this directory is not an endorsement.